+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Curcumin for Neurological and Psychiatric Disorders. Neurochemical and Pharmacological Properties

  • Book

  • March 2019
  • Elsevier Science and Technology
  • ID: 4720908

Curcumin for Neurological and Psychiatric Disorders: Neurochemical and Pharmacological Properties focuses on the different molecular mechanisms underlying curcumin-mediated beneficial effects in neurological diseases. The book's editors discuss the neurochemical and pharmacological properties of curcumin, followed by the effect of curcumin in neurotraumatic diseases, neurodegenerative diseases, and neuropsychiatric diseases. The book also offers a perspective on future studies on the treatment of neurological disorders.

The beneficial effects of curcumin have been observed both in cultured cells and in animal models, thus paving the way for ongoing present and future human clinical trials. Curcumin produces antioxidant and anti-inflammatory effects not only by blocking oxidative stress and neuroinflammation in neurotraumatic and neurodegenerative diseases, but also by restoring cellular homeostasis and rebalancing redox equilibrium.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

1. Neurological and neuropsychiatric disorders 2. Curcumin: Historical background, chemistry, pharmacological action and potential therapeutic value 3. Curcumin in neurological disorders 4. Curcumin in neurological disorders: An overview 5. The potential role of curcumin in treatment and prevention for neurological disorders 6. The chemistry and biological activities of curcuminoids: Impacts on neurological disorders 7. Pharmacological effects of curcuminoids in neurological disorders 8. Anti-oxidant properties of curcumin: Impact on neurological disorders 9. Omics and epigenetics of polyphenol mediated neuroprotection: The curcumin perspective 10. Curcumin offers potential efficacy for treating Alzheimer's disease 11. Potential role of curcumin and its derivatives against Alzheimer Disease 12. Usefulness of curcumin analogs for the diagnosis and treatment of Alzheimer Disease 13. Potential therapeutic impacts of curcumin against age-related impaired cognition and memory 14. Potential therapeutic impacts of curcumin for improving memory impairment 15. Curcumin derivatives as metal-chelating agents: Implications for potential therapeutic agent for neurological disorders 16. Neuroprotective propensity of Curcumin: evidences in animal models; Mechanisms and its potential therapeutic value 17. Molecular mechanisms of action of curcumin and its relevance to some clinical conditions 18. Therapeutic potentials of curcumin in Parkinson's disease 19. Beneficial role of curcumin in preventing the aggregation of the Amyloid-ß peptide in Alzheimer disease 20. Curcumin impact on multiple sclerosis 21. Potential therapeutic impacts of curcumin in treating epilepsy 22. The potential beneficial effects of curcumin in diabetic retinopathy 23. Current and combinative curcumin therapeutics for treating spinal cord injury 24. Curcumin and inflammatory brain diseases 25. Curcumin in depressive disorders 26. Summary, perspective and direction for future research


Tahira Farooqui Research Scientist, Department of Entomology/Center for Molecular Neurobiology, College of Biological Sciences, The Ohio State University, Columbus, OH, USA. Tahira Farooqui has published extensively on drug receptor interactions, biogenic amines in vertebrate and invertebrate nervous systems, biogenic amines mediated signaling, neural plasticity, as well as neuromoulatory roles of octopamine in the reinorcepathway involved in learning and memory, glycerophospholipid and sphingolipid metabolism and molecular signaling mechanisms in the brain. She is the author of 65 peer-reviewed research articles, one monographs and 8 edited books. She has coauthored a monograph in 2008 Metabolism and Function of Bioactive Ether Lipids in the Brain, 2008, by Springer, and have edited 8 Life Sciences books:1) Biogenic Amines: Pharmacological, Neurochemical, and Molecular Aspects in CNS, 2010, NOVA Science Publishers; 2) Phytochemicals and Human Health: Pharmacological and Molecular Aspects, 2011, NOVA Science Publishers; 3) Molecular Aspects of Neurodegeneration and Neuroprotection, 2011, Bentham Science Publishers; 4) Oxidative Stress in Vertebrates and Invertebrates: Molecular Aspects of Oxidative Stress on Cell Signaling, 2012, John Wiley & Sons, Inc; 5) Beneficial effects of propolis on human health and chronic diseases. Vol I, 2012, NOVA Science Publishers, Hauppage, New York; 6) Tahira Farooqui and Akhlaq A. Farooqui, Beneficial effects of propolis on human health and chronic diseases. Vol II, 2012, NOVA Science Publishers, Hauppage, New York; 7) Metabolic Syndrome and Neurological Disorders, 2013, John Wiley & Sons, Inc.; and 8) Diet and Exercise in Cognitive Function and Neurological Diseases, 2015, John Wiley & Sons, Inc. Akhlaq A. Farooqui Research Scientist, Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, OH, USA. Akhlaq A. Farooqui is a leader in the field of signal transduction processes, lipid mediators, phospholipases, glutamate neurotoxicity, and neurological disorders. He is a research scientist in the Department of Molecular and Cellular Biochemistry at The Ohio State University. He has published cutting edge research on the role of phospholipases A2 in signal transduction processes, generation and identification of lipid mediators during neurodegeneration by lipidomics. He has studied the involvement of glycerophospholipid, sphingolipid-, and cholesterol-derived lipid mediators in kainic acid neurotoxicity, an experimental model of neurodegenerative diseases. Akhlaq A. Farooqui has discovered the stimulation of plasmalogen- selective phospholipase A2 in brains of patients with Alzheimer disease (AD). Stimulation of this enzyme may not only be responsible for the deficiency of plasmalogens in neural membranes of AD patients, but also be related to the loss of synapse in the AD.